CAUTION: When reading this news item please be aware that the RejuvenAir System is an Investigational device, limited by United States Federal law to investigational use only. Not for Sale in the United States of America.
First Randomized Controlled Study with RejuvenAir for Chronic Bronchitis shows Clinically Significant Results
Metered Cryospray treats damaged airways enabling a rejuvenative healing response BOSTON, Sept. 6, 2022 /PRNewswire/ — CSA Medical, Inc., today announced results from the first randomized, controlled study of Metered Cryospray (MCS) utilizing the RejuvenAir®...
CSA Medical Announces Completion of Enrollment in Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis
These results should provide the scientific proof behind the remodeling response and clinical improvements identified in earlier studies Boston, MA—May 12, 2021: CSA Medical, Inc., today announced ® that all subjects have been enrolled in the RejuvenAir System study...
CSA Medical, Inc. Announces Cooper University Health Care is the 20th Clinical Site to Join the SPRAY-CB Pivotal Study for the treatment of Chronic Bronchitis
Boston, MA –April 19, 2021: CSA Medical, Inc., today announced that Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic...